Evotec: Healthy Cash Flows In The Future
Edison | Jun 29, 2016 07:48AM ET
Evotec AG O.N. (DE:EVTG) operates a hybrid business model and offers a unique risk-reward profile for investors, with steady growth from its EVT Execute business and potential drug development upside from its EVT Innovate arm. We base our investment thesis for Evotec on supportive company-specific and macro trends and forecast healthy cash flows in the future. Our valuation of Evotec is virtually unchanged at €575m.
Favourable macro and company-specific trends
Our investment thesis for Evotec is built on company-specific progress as well as positive industry trends that point towards healthy cash flows in the future. The drug discovery services industry continues to benefit from the need for R&D cost reduction and increasing comfort with outsourcing at pharma and biotech companies.
Service providers such as Evotec offer scalability, efficiency and flexibility with different outsourcing models, which all point towards continuing growth of the drug discovery services market. Due to the high-tech nature of drug discovery, quality of the service is key for long-term relationships and increasing integration level with customers, which also means higher margins.
For example, the total number of Evotec’s alliances increased significantly in 2014 and 2015 reaching 177, of which 67 were new clients. Twenty-one alliances generated more than €1m revenues each for Evotec, indicating a trend of an increasing number of quality customers.
To read the entire report Please click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.